IRF4公司
免疫系统
生发中心
肿瘤微环境
癌症研究
滤泡性淋巴瘤
生物
淋巴瘤
免疫学
干扰素调节因子
B细胞
转录因子
先天免疫系统
基因
抗体
遗传学
作者
Surendra Dasari,Kerstin Wenzl,Geoffrey M. Nelson,Emmanuel Contreras Guzman,Zhiquan Wang,Loïc Chartier,Zhi-Zhang Yang,José C. Villasboas,Olson Je,Prithviraj Mukherjee,Vaishali Bhardwaj,Xinyi Tang,Brianna J. Gysbers,Johannes L. Zakrzewski,Rebecca L. King,Sarah Huet,Bruno Tesson,Matthew J. Maurer,Franck Morschhauser,Grzegorz S. Nowakowski
标识
DOI:10.1158/2643-3230.bcd-24-0223
摘要
Abstract Twenty percent of follicular lymphoma (FL) patients relapse early with poor outcomes; however, the molecular mechanisms underlying this aggressive behavior are unknown. Using a multi-omics approach, we show that FL patients with elevated IRF4 expression (IRF4hi) have increased transformation risk, dysregulated immune signaling, and a suppressive tumor microenvironment. Loss- and gain-of-function experiments in IRF4hi lymphoma cells, along with chromatin profiling, demonstrate that IRF4 impairs their interaction with T cells by repressing antigen presentation and co-receptor gene modules, while promoting the expression of cytokines that antagonize TFH and Treg functions. Additionally, IRF4 rewires tumor metabolism which restricts glucose availability to immune cells. Silencing of IRF4 inhibits tumor cell growth and restores immune surveillance mechanisms, thus representing a promising target for therapy. Our data suggest that IRF4hi lymphoma cells co-opt a developmental mechanism used to exit the germinal center response in promoting a more aggressive cancer via engagement of multiple immune-evasive mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI